Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn, D.; Ricca, J.; Gasmi, B.; Mangarin, L. M.; De Henau, O.; Budhu, S.; Li, Y.; Cortez, C.; Xia, Y.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Isoform specific TGF-β inhibition in combination with radiation therapy as a novel immune therapeutic approach to cancer therapy
    Meeting Abstract

    Gupta, A.; Budhu, S.; Giese, R.; van Snick, J.; Uyttenhove, C.; Ritter, G.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Characterization of the anti-CTLA-4 antibody AGEN1884, including toxicology and pharmacology assessments in non-human primates
    Meeting Abstract

    Gombos, R.; Gonzalez, A.; Manrique, M.; Chand, D.; Savitsky, D.; Morin, B.; Breous-Nystrom, E.; Dupont, C.; Ward, R.; Mundt, C.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • AGEN2034, a novel anti-PD-1 antibody that combines effectively with CTLA-4 pathway blockade to enhance T cell activity
    Meeting Abstract

    Chand, D.; Savitsky, D.; Gonzalez, A.; Clarke, C.; Schuster, A.; Drouin, E. E.; Waight, J. D.; Mundt, C.; Ritter, G.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
    Meeting Abstract

    Budhu, S.; Giese, R.; De Henau, O.; Zappasodi, R.; Campesato, L. F.; Gupta, A.; Barker, C.; Freimark, B.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • FRACTION-RCC: A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC
    Meeting Abstract

    Taitt, C. C.; Motzer, R. J.; Choueiri, T. K.; Escudier, B. J.; Kuzel, T.; Carducci, M. A.; Nair, S.; Tykodi, S. S.; Tannenbaum-Dvir, S.; Wind-Rotolo, M.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
    Meeting Abstract

    Ribas, A.; Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Brail, L.; Lee, L.; Mahabhashyam, S.; Ullmann, C. D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • KEYNOTE-585: Randomized, phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer
    Meeting Abstract

    Bang, Y. J.; Van Cutsem, E.; Fuchs, C.; Ohtsu, A.; Tabernero, J.; Ilson, D.; Hyung, W. J.; Strong, V.; Goetze, T.; Yoshikawa, T.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study)
    Meeting Abstract

    DeAngelo, D. J.; Ghobadi, A.; Park, J. H.; Dinner, S. N.; Mannis, G. N.; Lunning, M. A.; Khaled, S. K.; Fathi, A. T.; Gojo, I.; Wang, E. S.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Long-term survival in patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab
    Meeting Abstract

    Topalian, S. L.; Hodi, F. S.; Brahmer, J. R.; Gettinger, S. N.; Smith, D. C.; McDermott, D. F.; Powderly, J. D.; Sosman, J. A.; Atkins, M. B.; Spigel, D. R.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save